Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I can't have all of the answers.
I believe that if it wasn't accepted, investors would have known, not?
If the paper has been submitted in October, shortly it would be 5 months into that process. Time is coming, however, without any meaningful news and/or the publication, I don't see any catalysts that would push the stock price up.
Would be nice if it would close green.
Who's unloading?
No, management or workers's buyouts are usually seen as friendly buyouts.
Management is the "subject" of the buyout. Is't a buyout made by management. The only difference between a sale to third parties is that management decided to buy the company from share/stake holders.
It's a buyout (not a sale of assets), so no need to report anything as the shares did not change hands IMO. However, it is quite obvious that if Cognate would decide to sell all of its shares, the share price of the co. would crater. In my opinion, in order to avoid this, I do believe that in the sale's agreement there were lock-up provisions for a certain amount of time (eventually accelerated in case of release of interim data and / or PIII results).
The one thing I am more surprised about, is that there's no news around at all. I mean, wasn't a trial supposed to start in January? Did it or did it not? When do they expect to report topline, this year or who knows? I mean, even a very small news would be welcomed.
Most likely. The problem is: when will the publication hit the news? I am starting to think it might take even April or May, though some people have speculated even February.
Don't agree. Topline will come after interim blinded and interim blinded I don't think will be published very shortly (this month or so). ASCO is "only" 4 months away, IMO the right time to release topline if "2018 refresh" is good enough.
I don't see any correlation, do you?
This presentation will be interesting. Please keep the MB updated.
I agree that it started on the 2017 "refresh".
However you take it, lots of info around point to the fact that it usually takes 6-9 months after submission to have it published.
Besides that, if they publish tomorrow that would be great (because I suspect stock price will appreciate on it), but I still think it will take some months.
If last month they were a couple of months into the process, it's IMO very difficult they will publish within next 6 weeks.
First off, the most important thing was that at the ASM it was finally confirmed that the paper was submitted. Secondly, it was much important to know when it was submitted, because at least it sets a milestone in the timeframe.
That said, I believe that knowing (or guessing) more or less when the paper will be published (and thus trying to shed some light on the 6-9 months issue) is important for of all those that, me included, do believe it could ba a catalyst.
Best wishes.
Well, it looks quite obvious to me, because that would not be possible to consider start of the process at the beginning of June and being in a couple of months of that process. Anyhow, besides this timing different views, do you see other catalysts than the combo trial starting? As I don't see it really as a catalyst for stock appreciation. Something else in your view?
I see that you imply that it could me a minimum of 4 months (not 2). Besides it, what would you think could be a catalyst in this timeframe, if you believe there would be any at all?
6-9 months timeframe is what has been said in this message board, starting from submission. I understand you don't have an answer, but the question is for those people who want to share possible catalysts in the meanwhile. But thank you for your time.
So, if the publication has been submitted in the fall, and it takes about 6-9 months, and optimistically supposing it was submitted at the end of September, there should be news at the end of March (two months from now). What do you guys believe are the possible cathalysts in these upcoming two months?
That's nonsense. I believe the ASM should have no effect on the share price. It was not intended to bring significant news to shareholders. Companies do that via 8ks or Prs when the info is available.
Obvioulsy not and you know that.
The things I am looking for are very easy and simple:
1) Publication: first hinted on June '17 and still no news (8 months have passed!);
2) Interim blinded data: they said they will release them (with no specific timeline), and 4 months have passed, and nothing yet.
3) SEC investigation: I believe news about results (bad or good) are imminent.
ASM on a Sunday is scheduled for some reason I guess
Calling shareholders to vote is also strange
Either was the buying volume.
Totally off radar. It's not a surprise when numbers are thrown up without any underlined DD.
Maybe IMO something like "the FDA execs are still looking at the company at the moment"??? or something like that? Not very clear.
Oh, I see...there's a plan!
You mean just like the investigation results?
Any security will be adjusted accordingly.
That is math, imo.
There we go...
Even worse, that would mean more authorized shares.
Was it China that suggested the possibility of 2B shares and everybody seemed to laugh at the idea?!?
TO me it means by sure no news untill the 28th...or even later than that.
LOL, where is the publication and where interim blinded data??!
Interim blinded results?!?
It's irresponsible, imo, not to ask what is up
Great, would you mind to rewatch the ASCO 2017 presentation and then see if what you state is validated?